April 18, 2013 at 17:20 PM EDT
Theravance's Breo Ellipta Receives Approval Recommendation
A Food and Drug advisory panel recommended approval for Theravance Inc.'s (Nasdaq: THRX) Breo Ellipta inhaler. Shares of the biopharmaceutical leaped $4.55 to close at $32.56.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here